Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study

Journal of Clinical Oncology

Volumn 30, Issue 16, 2012, Pages 1989-1995

  Guarneri, Valentina ^a   Frassoldati, Antonio ^a   Bottini, Alberto ^b   Cagossi, Katia ^c   Bisagni, Giancarlo ^d   Sarti, Samanta ^e   Ravaioli, Alberto ^f   Cavanna, Luigi ^g   Giardina, Giovanni ^h   Musolino, Antonino ⁱ   Untch, Michael ^l   Orlando, Laura ^j   Artioli, Fabrizio ^c   Boni, Corrado ^d   Generali, Daniele Giulio ^b   Serra, Patrizia ^e   Bagnalasta, Michela ^k   Marini, Luca ^k   Piacentini, Federico ^a   D'Amico, Roberto ^a   Conte, PierFranco ^a   more..

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b CREMONA HOSPITAL   (Italy)

^c Ramazzini Hospital   (Italy)

^d S MARIA NUOVA HOSPITAL   (Italy)

^e DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^f Osp Infermi   (Italy)

^g Hospital of Piacenza   (Italy)

^h OSPEDALE DI CIRCOLO   (Italy)

ⁱ UNIVERSITY HOSPITAL OF PARMA   (Italy)

^j 'Sen Antonio Perrino' Hospital   (Italy)

^k GSK   (Italy)

^l HELIOS KLINIKUM BERLIN BUCH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; PACLITAXEL; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DIARRHEA; FATIGUE; HISTOPATHOLOGY; HUMAN; HYPERSENSITIVITY REACTION; LIVER TOXICITY; LOADING DRUG DOSE; MUCOSA INFLAMMATION; NAUSEA; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 84864018421     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.0823     Document Type: Article

References (32)

1. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344:783-792, 2001
2. Marty M, Cognetti F, Maraninchi D, et al: Randomised phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005
3. Piccart-Gebhart MJ, Procter M, Leyland- Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 353:1659-1672, 2005
4. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med 353:1673-1684, 2005
5. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
6. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
7. Nahta R, Esteva F: Molecular mechanism of trastuzumab resistance. Breast Cancer Res 8:215, 2006
8. Konecny GE, Pegram MD, Venkatesan N, et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639, 2006
9. Spector NL, Xia W, Burris H III, et al: Study of the biological effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23:2502-2512, 2005
10. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
11. Cameron D, Casey M, Press M, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analysis. Breast Cancer Res Treat 112:533-543, 2008
12. Di Leo A, Gomez H, Aziz Z, et al: Phase III, double blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first line treatment for metastatic breast cancer. J Clin Oncol 26:5544-5552, 2008
13. Nahta R, Yuan LX, Du Y, et al: Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor 1 signaling. Mol Cancer Ther 6:667-674, 2007
14. Scaltriti M, Verma C, Guzman M, et al: Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28:803-814, 2009
15. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010
16. Blackwell KL, Burstein HJ, Sledge GW, et al: Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 (abstr 61)
17. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
18. Rastogi P, Anderson SJ, Bear HD, et al: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785, 2008
19. Guarneri V, Broglio K, Kau SW, et al: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037-1044, 2006
20. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281, 2008
21. Rouzier R, Extra JM, Klijanienko J, et al: Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20:1304-1310, 2002
22. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathological tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
23. Hennessy BT, Hortobagyi GN, Rouzier R, et al: Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23:9304-9311, 2005
24. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in Human Epidermal Growth Factor Receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685, 2005
25. Untch M, Rezai M, Loibl S, et al: Neoadjuvant treatment with trastuzumab in HER-2 positive breast cancer: Results from the GeparQuattro study. J Clin Oncol 28:2024-2031, 2010
26. Gianni L, Eiermann W, Semiglazov V, et al: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377-384, 2010
27. Untch M, Fasching PA, Konecny GE, et al: Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in Human Epidermal Growth Factor Receptor 2-overexpressing breast cancer: Results from the TECHNO trial of the AGO and GBG Study Groups. J Clin Oncol 29:3351-3357, 2011
28. Gralow JR, Burstein HJ, Wood W, et al: Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26:814-819, 2008
29. US Food and Drug Administration: Guidance for Industry: Drug-Induced Liver Injury - Premarketing Clinical Evaluation. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdflast
30. Untch M, Loibl S, Bischoff J, et al: Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44). San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr S3-1)
31. Gianni L, Pienkowski T, Im Y-H, et al: Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study ('NeoSphere'). San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr S3-2)
32. Baselga J, Bradbury I, Eidtmann H, et al: First results of the NeoALTTO Trial (BIG 01-06/ EGF 106903): A phase III, randomized, open label, neo-adjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr S3-3)